Poly-oxygenated Aluminum Hydroxide for Oxygen Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional oxygen therapies, such as hyperbaric oxygen therapy, are limited by the small concentration of oxygen delivered and are expensive and not widely available, while existing poly-oxygenated metal hydroxides like Ox66™ have therapeutic benefits but require particle size reduction for effective delivery methods like intravenous, nasal, and topical administration.
Innovation Solution
A chlorine-free poly-oxygenated aluminum hydroxide composition with particles sized ≤212 μm, engineered to be soluble and bioavailable, allowing for precise delivery forms such as nanoparticles for enhanced therapeutic applications, including intravenous, inhalation, and topical treatments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If conventional gaseous oxygen delivery methods are used, then oxygen can be delivered to patients, but the concentration of oxygen delivered is small and the treatment is expensive and not widely available
Solution Approach 1:
The patent transforms oxygen from a gaseous state to a dissolved state within metal hydroxide particles. This parameter change (from gas to dissolved form) enables much higher oxygen concentration to be delivered in a compact, stable form that can be administered through various routes without requiring expensive hyperbaric chambers.
Solution Approach 2:
The patent uses metal hydroxide particles as an intermediary carrier to transport oxygen. Instead of delivering oxygen directly as gas, the oxygen is bound within the metal hydroxide structure, which then releases it at the target site. This intermediary approach enables controlled delivery and dramatically increases the effective oxygen concentration that can be transported.
2Reliability
If poly-oxygenated metal hydroxide particles are used for therapy, then therapeutic benefits are achieved, but particle size must be reduced for effective delivery through intravenous, nasal, and topical routes
Solution Approach 1:
The patent segments the poly-oxygenated metal hydroxide into extremely fine particles with diameters of 0.1-10 micrometers. This segmentation allows the particles to pass through biological barriers (veins, nasal passages, skin) that would block larger particles, while still maintaining the therapeutic oxygen-carrying capacity of the original material.
Solution Approach 2:
The patent transitions from delivering oxygen in a gaseous dimension (requiring large chambers) to delivering it in a particulate dimension that can be administered through standard medical routes. This dimensional change enables the same therapeutic benefit to be achieved through much more accessible delivery methods.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables revolutionary oxygen therapy applications by ensuring bioavailability and solubility, allowing for effective treatment of conditions like traumatic brain injury, internal burns, and enhanced oxygenation of tissues, with reduced immune response and improved bioavailability.
Implementation Method 1
a clathrate containing oxygen gas molecules that are soluble in a fluid
Implementation Method 2
the clathrate is chlorine-free and comprises particles each having a diameter of less than or equal to 212 μm such that the particles pass through a sieve with mesh size 212 μm and which may comprise a nutraceutical. The poly-oxygenated aluminum hydroxide is soluble in the fluid.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
A composition of chlorine-free poly-oxygenated metal hydroxide that comprises a clathrate containing oxygen gas molecules, and which may comprise a nutraceutical. In one embodiment, the poly-oxygenated metal hydroxide composition is soluble, and may have particles having a diameter of 212 μm or less. The poly-oxygenated metal hydroxide may comprise of a poly-oxygenated aluminum hydroxide. The nutraceutical may include one or more of a protein, vitamin, fiber, mineral and electrolytes. The composition may be in a powder or fluid form, where the poly-oxygenated aluminum hydroxide is soluble in the fluid.